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Background: Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating disease that leads to important
morbidity and mortality in a young patient population. Anemia following aSAH is common and may be
exacerbated by the treatments instituted by clinicians as part of standard care. The role and optimal thresholds for
red blood cell (RBC) transfusion in this patient population remains unknown.
Methods/design: We will conduct a systematic review of the literature using MEDLINE, EMBASE, and EBM Reviews
(including Cochrane Central databases) using a comprehensive search strategy for observational and interventional
studies of RBC transfusion in aSAH. Our primary objective is to evaluate the association of RBC transfusion with
mortality in aSAH patients. Secondary objectives include a) determining associations between RBC transfusion and
poor neurologic outcome, b) defining an optimal RBC transfusion threshold in aSAH patients, and c) describing
complications associated with RBC transfusion in aSAH patients. We plan a descriptive reporting of all included
citations including study characteristics, methodological quality, and reported outcomes. Clinical and statistical
heterogeneity observed between studies will be described. If appropriate, meta-analyses of suitable studies and
interpretation of their results will be performed. Effect measures will be converted to obtain relative risks and odds
ratios (RR and ORs) with 95% confidence intervals and pooled according to study design (randomized trials and
observational studies respectively) using a random effects model.
Discussion: This review will summarize the existing observational and trial evidence regarding RBC transfusion in
aSAH patients. The analytical plan has made considerations for different study designs, both observational and
interventional in nature, and will summarize the best available evidence to inform the end user and policy and
guideline producers and to highlight areas in need of further study.
Systematic review registration: PROSPERO CRD42014014806
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Aneurysmal subarachnoid hemorrhage (aSAH) has an
estimated incidence rate of 10 per 100,000 patient years
in the general population [1,2] and is a common neuro-
logic cause for intensive care unit (ICU) admission [3].
It affects a relatively young population [4] and thus* Correspondence: senglish@ohri.ca
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unless otherwise stated.accounts for significant potential years of meaningful life
lost [5] given the important morbidity and mortality the
disease imports. Mortality remains high affecting almost
50% of the patients afflicted with aSAH [1,4,6-8].
The period that follows the acute hemorrhage is fraught
with multiple possible complications. Anemia is common,
affecting more than 50% of aSAH patients [9,10], and is
independently associated with poor outcome after SAH
[11,12], regardless of SAH severity [13]. Although anemia
is defined by the World Health Organization as a
hemoglobin of less than 130 g/L in men and 120 g/L in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vant in SAH populations when moderate (or ≤100 g/L) in
both [9,10]. Anemia develops a mean of 3.5 days from ad-
mission [9], which coincides with the typical onset of an-
other important complication, vasospasm.
Vasospasm is seen in 50% to 75% of patients with
aSAH [4,15] leading to ischemic injury or delayed ische-
mic neurologic deficits (DINDs) from reduced cerebral
perfusion. Standard of care management of vasospasm
includes hyperdynamic therapy [4], which traditionally
included hypertension, hypervolemia and hemodilution
(the so-called ‘HHH therapy’). By its very nature, it may
lead to or exacerbate anemia. Interestingly, there appears
to be stronger data supporting hypertension as being the
most beneficial aspect of hyperdynamic therapy in main-
taining adequate cerebral perfusion [16] (and hence oxy-
gen delivery) while hemodilution, and its effects on
hemoglobin concentration, is considered to be poten-
tially harmful [17].
Recent techniques of micropipetting and monitoring of
brain tissue partial pressure of oxygen bring evidence to
suggest brain tissue at risk from ischemia benefit from im-
proved oxygen delivery [18,19]. Observational work has
shown that brain tissue partial pressure of oxygen is
higher with higher hemoglobin concentrations [19] and
increases with red cell transfusion [20]. However, transfu-
sion in critically ill patients remains a hotly debated issue.
The landmark TRICC trial drastically changed how critic-
ally ill patients are managed with respect to RBC transfu-
sion with their finding that a restrictive transfusion
strategy (Hb trigger of ≤70 g/L) was as safe as a liberal
strategy (Hb trigger ≤100 g/L) and trended towards better
outcome [21]. This study, however, is not necessarily
generalizable to an aSAH population, as very few patients
with neurologic diagnoses were included. Observational
work in aSAH has shown that both anemia and red cell
transfusion are each risk factors for poor outcome [12,22].
Further, evidence is conflicting as to which of anemia or
transfusion carries the bigger risk, or if a risk exists at all
[12,23-26]. A recent systematic review examined transfu-
sion thresholds among all neurocritical care patients but
was limited to those studies that compared at least two
different thresholds [27]. As such, only six studies met in-
clusion for this review, only one of which included aSAH
patients. Our knowledge synthesis will examine the
current clinical evidence around anemia and RBC transfu-
sion thresholds and the effect of transfusion on death,
neurologic outcomes, and transfusion adverse events
among critically ill patients with aSAH.
Objectives
The primary objective of this review is to evaluate the
association of RBC transfusion with mortality in aSAH
patients. Mortality will be assessed as reported at hospitaldischarge, 30 days, and 3, 6, and 12 months. Secondary
objectives include 1) determining associations between
RBC transfusion/liberal transfusion strategy and poor
neurologic outcome (as measured by any of modified Ran-
kin Scale (mRS) ≥4, Glasgow Outcome Scale (GOS) ≤3, or
extended Glasgow Outcome Scale (eGOS) ≤4), 2) defining
an optimal RBC transfusion threshold in aSAH patients,
and 3) describing transfusion adverse events associated
with RBC transfusion in aSAH patients.
Methods/design
This review will be conducted in accordance with The
Cochrane Collaboration [28] principles for Systematic Re-
views and reported following the PRISMA guidelines [29].
Search strategy
Our search strategy will be conducted using MEDline +
MEDline In-Process & Other Non-indexed Citations,
EMBASE Classic + Embase, and EBM Reviews (including
Cochrane Central databases) from inception to the mo-
ment of review (see Appendix). EMBASE also includes
the abstract publications from major international con-
ferences including the International Stroke Conference,
Neurocritical Care Society Meeting, Society of Critical
Care Medicine, and the International Symposium on In-
tensive Care and Emergency Medicine. A comprehensive
search strategy will be constructed and implemented by
a health information specialist with systematic review
experience, in collaboration with the research team.
MeSH terms will be used to capture each of the princi-
pal elements of the research question. To be as inclusive
as possible, the strategy will be restricted to focusing on
population (aSAH patients) and intervention/exposure
(RBC transfusion) and will not be limited by outcome
studied. So as to not overlook any possible study for in-
clusion, our search strategy will include anemia as a
search term, separate from transfusion. Our study inter-
vention of RBC transfusion will be targeted by applying
inclusion and exclusion criteria as described below.
Upon completion, identified citations will be exported to
a citation manager (Mendeley Desktop, Mendeley Ltd.,
v. 1.12.2) for study selection. Manual review of the refer-
ence lists of all included studies and previous systematic
reviews will be conducted. A final grey literature search
will be conducted using ‘Google Scholar’ as well as a re-
view of the trial register (clinicaltrials.gov) for any on-
going and unpublished studies. No language restriction
will be utilized in any of the searches. Duplicate citations
will be removed. The search strategies will be kept up to
date to the time of the end of the review.
Study screening and inclusion
Both observational (cohort, cross-sectional) and inter-
ventional studies will be considered. We will include all
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tailing all of the available evidence regarding RBC transfu-
sion in aSAH patients. We aim not only to consider
comparative studies of different transfusion thresholds as
has been done in the past [27] but also to include studies
that compare exposed from non-exposed patients.
An iterative process for study selection will be fol-
lowed using the criteria set out in Table 1. Specifically,
we will include all interventional or observational studies
that report on an adult (age ≥18 years) hospitalized
aSAH population (population), examine RBC transfusion
(intervention) and compare either two or more different
thresholds or to a non-transfused group (comparator),
and report on any clinical outcome (outcome). We will
exclude any study which reports exclusively on a
pediatric population (age <18 years), non-human studies,
and any duplicate or sub-study of previously published
(and included) cohorts. All records will first be screened
by title and abstract. All citations clearly not relevant to
the review (for example, wrong population, pre-clinical
study, narrative review) will be excluded. This process
will be performed in duplicate by two independent re-
viewers. Any citation in which an abstract is not avail-
able and where suitability for inclusion is questioned will
proceed to the next stage. All citations not excluded in
the first screen will have full articles retrieved for a sec-
ond review, in duplicate by independent reviewers, and
the selection criteria applied. Any differences in classifi-
cation between the two independent reviewers will be
reviewed and consensus decision made. A third inde-
pendent senior reviewer will be used in any instance in
which consensus is not reached.
Our study free-form question is: In adult patients (age
≥18 years) with acute aSAH, is RBC transfusion or a lib-
eral RBC transfusion strategy associated with increased
all-cause mortality? We will deem the intervention arm
(for interventional studies) or exposure (for observa-
tional studies) to be the liberal transfusion strategy or
any RBC transfusion respectively administered during
the initial hospitalization for aSAH. We will compare this
to a restrictive transfusion strategy or non-transfusedTable 1 Study selection criteria
Inclusion criteria Exclusion criteria
1. Study design: interventional
or observational
1. Studies of exclusively pediatric
population (age <18 years)





3. Duplicates or ‘sub-cohorts’ of
previously published cohorts
4. Comparator: a different
transfusion threshold or
no transfusion
5. Study outcome: anypatients with aSAH. Our primary outcome is all-cause
mortality. We will examine hospital mortality and mortal-
ity at 30 days as well as 3, 6, and 12 months. We will also
examine the following secondary outcomes: 1) poor
neurologic recovery (modified Rankin Scale ≥4, GOS ≤3,
eGOS ≤4) based on the last follow-up time point, at hos-
pital discharge, and at 3, 6, and 12 months; 2) hospital and
ICU length of stay; 3) optimal RBC transfusion threshold;
4) transfusion adverse events; and 5) vasospasm and cere-
bral infarct incidence.
Data extraction
A data extraction form will be prepared a priori and
piloted prior to duplicate extraction by two independent
reviewers. Data extraction will include:
Study characteristics, design, and methods: title, authors,
journal/source, year and language of publication,
country, type of study, study period, total number of
patients, case ascertainment and/or inclusion/exclusion
criteria, randomization, allocation concealment, and
blinding methods (where applicable)
Sample characteristics: age, sex, admission diagnosis,
aSAH grade, aneurysm size and location, comorbidities,
and baseline hemoglobin
Interventions and co-interventions: aneurysm clip or coil
procedures, vasopressor use, mechanical ventilation,
externalized ventricular drain (EVD), hyperdynamic (or
‘HHH’) therapy, and RBC transfusion
Outcome: study-specific outcomes as defined by the
authors will be captured. In addition, we will abstract
nadir hemoglobin, time to nadir hemoglobin,
pre-transfusion hemoglobin, ICU admission, clinical
complications (including vasospasm and infarction),
functional recovery (including mRS, GOS, and eGOS),
mortality, and other adverse events
Analysis plan
A description of all included studies, including demo-
graphic, clinical, and methodological quality (see risk of
bias), will first be reported with the aid of tables and
text. Our cursory review of the literature and a recent
narrative review [10] suggests that several observational
studies exist that will be the focus of this review. Meta-
analyses of observational studies are at particular risk of
bias and confounding [30]. Therefore, suitability for
meta-analysis will be determined by the degree of het-
erogeneity (clinical and statistical) observed between the
studies. Statistical heterogeneity will be described using
the I2 statistic.
Primary outcome
We anticipate that the primary outcome, all-cause mor-
tality, may be reported differently according to the study
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to exposed/not exposed, using a threshold strategy or a
cumulative exposure. Where possible, we will collect the
crude numbers of dead and alive patients in each respect-
ive group (for example, exposed/non-exposed) at the latest
follow-up time point per the study-specific design as well
as their associated crude and adjusted effect measures in-
cluding relative risk (RR), odds ratio (OR), and hazard ra-
tio (HR). Should a meta-analysis be deemed appropriate,
effect measures will be converted to obtain RRs for RCTs
and ORs for observational studies with 95% confidence
intervals (CIs) and pooled according to study design (for
example, RCTs vs observational studies, transfused vs
non-transfused, comparative threshold studies). Given that
we anticipate a certain degree of heterogeneity, a random
effects model will be used. Statistical heterogeneity will be
reported using the I2 test with 95% confidence interval.
Secondary outcomes
Secondary outcomes will be a combination of dichotom-
ous, ordinal, and continuous measures. Effect estimates
of dichotomous outcomes will be presented as RR or
ORs and 95% CIs. If appropriate, we will perform meta-
analysis, and data presented as a RR will be converted to
OR where possible. Neurologic outcomes (mRS, GOS,
and eGOS) are expected to be presented either as or-
dinal data or may have already been dichotomized by
the authors. Where possible, ordinal neurologic out-
comes will be utilized. All continuous outcome variables
will be described with means or medians and associated
standard deviations or interquartile ranges as appropri-
ate. Summaries of continuous data will be presented as
mean differences with 95% confidence intervals.
Optimal transfusion hemoglobin threshold To describe
an optimal hemoglobin transfusion threshold, studies
will be grouped according to whether different transfu-
sion thresholds were assessed or if pre-transfusion
hemoglobin levels were reported. When a transfusion
threshold is the intervention of interest, we will group
the results of the lower and higher thresholds for com-
parison. We will pool the results from studies using
similar thresholds (for example, hemoglobin within
10 g/L). If our review includes a sufficient number of
studies that assess thresholds in regard to a specific out-
come, a meta-regression analysis will be performed to
assess the risk of that outcome in regard to the different
reported thresholds [31]. In the event of reporting of
ranges of pre-transfusion hemoglobin, the exposure will
be assigned as the midpoint of the range.
Risk of bias
Risk of bias will be assessed using the Downs and Black
tool [32] for observational studies and the CochraneCollaboration tool for assessing the risk of bias in RCTs
[33]. Bias risk assessment will be completed in a similar
fashion as the study selection process: in duplicate by
two independent assessors. Cases of discordance not re-
solved by consensus will be reviewed by a third senior
assessor. Risk of bias assessment of all included studies
will be summarized and presented in table format.
Meta-analysis, if possible, will be performed including all
studies, with a planned sensitivity analysis (see below) to
be performed using only those studies at low risk of bias.
Low risk of bias will be defined as those studies with a
score of ≥25 using the Downs and Black tool or those
deemed low risk across all domains of the Cochrane
Collaboration’s tool for assessing risk of bias. The au-
thors recognize that no formal cutoffs exist to define low
or high risk of bias with the Downs and Black tool (writ-
ten correspondence with the author); however, we deem
that in order for low risk of bias to exist in an observa-
tional study, there must be excellent reporting, high in-
ternal and external validity with little risk of confounding,
and sufficient study power (all domains assessed with this
tool) such that high scores in each of these domains are
necessary to meet low-risk criteria.
Subgroup analyses Pre-planned subgroup analyses to
examine clinical heterogeneity will include transfusion in
anemic patients (hemoglobin ≤100 g/L), first transfusion
pre/post vasospasm and transfusion in high-grade aSAH
patients (defined as Hunt and Hess grades 4 to 5, and/or
Fisher grade 4, WFNS grades 4 to 5), and open surgical
clipping versus endovascular coiling.
Sensitivity analyses To test the robustness of our find-
ings, we plan the following sensitivity analyses: 1) studies
with low versus unclear/high risk of bias, 2) studies with
study periods after 2005 (the year of the ISAT trial [34]
publication which resulted in a management shift from
surgical clipping to interventional coiling of certain an-
eurysms) versus before 2005, and 3) studies in which im-
portant confounders of RBC transfusion and mortality,
such as aSAH severity, pre-transfusion and hemoglobin
nadir, and vasospasm, are controlled for in their primary
analysis.
Discussion
Subarachnoid hemorrhage is a devastating event often
with lasting effects that greatly impact functionality and
quality of life. The natural history of subarachnoid
hemorrhage often includes complications like vasospasm
that leads to further injury from ischemic damage whose
very treatment may lead to hemodilution, potentially fur-
ther compromising oxygen delivery. This rather uniquely
sets apart this population from others in which a restrict-
ive transfusion strategy has been shown to be at least as
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strictive transfusion strategy is not clearly beneficial for
SAH patients, and doubt has been cast with small inter-
ventional studies involving other end-organ ‘at-risk’ popu-
lations [37].
This review proposes to systematically identify, gather,
and summarize the observational and trial evidence that
exists regarding RBC transfusion in SAH patients, using
a rigorous methodology. We aim to assess the effect of
RBC transfusion on all-cause mortality in addition to
other clinically important outcomes which will serve as
a summation of the evidence to best inform clinical de-
cisions at the bedside.
We anticipate that the majority of available evidence
will be the results of observational work rather than ran-
domized controlled trials. As such, we have planned for
a large descriptive component of this review which will
include tables, figures, and charts. We recognize that the
risk of bias is much higher, particularly in retrospective
observational studies and as such have incorporated into
the protocol two well-recognized and accepted assess-
ment tools in addition to planned assessments of clinical
and statistical heterogeneity. The results from observa-
tional studies may be inflated as was the experience in a
recent systematic review of large-scale observational
studies assessing the effect of transfusion on mortality in
a heterogeneous patient population [38]. Although their
findings were consistent across studies despite varying
study designs and degrees of confounding adjustment, the
magnitude of the findings were significantly larger with
the observational studies. Nonetheless, clinicians are often
forced to turn to observational studies to inform practice,
since well-conducted randomized controlled trials are very
limited in number. In fact, in SAH, the vast majority of
the related recommendations in the most recent guide-
lines are based on observational evidence or expert
opinion alone [39]. This review will formulate the best
available evidence, which is dependent on the quality of
the existing evidence. Careful interpretation of the find-
ings, in light of identified limitations, is essential.
This knowledge synthesis thus will not only serve to
inform the end user (that is, the clinician) but also policy
and guideline producers. Finally, this review is essential
to further highlight areas in need of further study. It will
inform the creation of other scientific questions and help
formulate other research protocols.
Appendix
Search strategy
The following databases will be used to conduct our
search strategy:
1. MEDline +MEDline In-Process & Other Non-indexed
Citations (1946 to present)2. EMBASE Classic + Embase (1947 to present)
3. EBM Reviews (incl Cochrane) (2005 to present)
4. Search of trial registers for ongoing and
unpublished studies
SAMPLE search strategy
Database: Embase Classic + Embase <1947 to present>,
Ovid MEDLINE(R) In-Process & Other Non-Indexed
Citations and Ovid MEDLINE(R) <1946 to present>
Search strategy:
1 exp Subarachnoid Hemorrhage/ (44404)
2 *intracranial hemorrhages/ or *cerebral
hemorrhage/ or *vasospasm, intracranial/ (45036)
3 *Intracranial Aneurysm/ (27317)
4 *Rupture, Spontaneous/ or *rupture/ or rupture$.tw.
(207853)
5 3 and 4 (7647)
6 *Aneurysm, Ruptured/ (8661)
7 exp *brain/ or exp *meninges/ (1256700)
8 6 and 7 (430)
9 ((subarachnoid or arachnoid$) adj3 (haemorrhag$
or hemorrhag$ or haematoma$ or hematoma$ or
bleed$ or blood$)).tw. (40217)
10 ((brain or cereb$ or intracranial) adj3 aneurysm$
adj3 ruptur$).tw. (6251)
11 ((brain or cereb$ or intracranial) adj3 aneurism$
adj3 ruptur$).tw. (30)
12 ((cerebral or intracranial or cerebrovascular) adj6
(vasospasm or spasm)).tw. (8794)
13 sah.tw. (15075)
14 1 or 2 or 5 or 8 or 9 or 10 or 11 or 12 or 13
(101951)
15 Erythrocyte Transfusion/ (18728)
16 ((red blood cell$ or rbc or erythrocyte$ or red cell$)
adj2 (transfus$ or therap$)).tw. (14636)
17 *Blood Transfusion/ (67415)
18 rbct.tw. (125)
19 (blood adj2 transfus$).tw. (89864)
20 (hemotransfus$ or haemotransfus$).tw. (522)
21 or/15-20 (148295)
22 14 and 21 (371)
23 *anemia/ or anemia.tw. or anaemia.tw. (267609)
24 14 and 23 (498)
25 *Hemoglobins/ or hemoglobin$.ti. orhaemoglobin$.ti.
(100884)
26 14 and 25 (265)
27 22 or 24 or 26 (1012)
28 animals/ not humans/ (5123176)
29 27 not 28 (949)
30 29 use emczd (622) EMBASE
31 exp Subarachnoid Hemorrhage/ (44404)
32 intracranial hemorrhages/ or cerebral hemorrhage/
or vasospasm, intracranial/ (94172)
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34 Rupture, Spontaneous/ or rupture/ or rupture$.tw.
(227167)
35 33 and 34 (9450)
36 Aneurysm, Ruptured/ (15457)
37 exp brain/ or exp meninges/ (2087107)
38 36 and 37 (1927)
39 ((subarachnoid or arachnoid$) adj3 (haemorrhag$
or hemorrhag$ or haematoma$ or hematoma$ or
bleed$ or blood$)).tw. (40217)
40 ((brain or cereb$ or intracranial) adj3 aneurysm$
adj3 ruptur$).tw. (6251)
41 ((brain or cereb$ or intracranial) adj3 aneurism$
adj3 ruptur$).tw. (30)
42 ((cerebral or intracranial or cerebrovascular) adj6
(vasospasm or spasm)).tw. (8794)
43 sah.tw. (15075)
44 31 or 32 or 35 or 38 or 39 or 40 or 41 or 42 or 43
(145988)
45 Erythrocyte Transfusion/ (18728)
46 ((red blood cell$ or rbc or erythrocyte$ or red cell$)
adj2 (transfus$ or therap$)).tw. (14636)
47 Blood Transfusion/ (145644)
48 rbct.tw. (125)
49 (blood adj2 transfus$).tw. (89864)
50 (hemotransfus$ or haemotransfus$).tw. (522)
51 or/45-50 (199301)
52 44 and 51 (1576)
53 anemia/ or anemia.tw. or anaemia.tw. (321603)
54 44 and 53 (1752)
55 Hemoglobins/ or hemoglobin$.ti. orhaemoglobin$.ti.
(207188)
56 44 and 55 (1173)
57 52 or 54 or 56 (3847)
58 animals/ not humans/ (5123176)
59 57 not 58 (3698)
60 59 use prmz (625) MEDLINE
61 30 or 60 (1247)
62 remove duplicates from 61 (957)
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